Company: CPMV
Filing Date: 2025-04-15
Form Type: 10-K
Source: 0001683168-25-002584
Chunk: 166

Company: Mosaic ImmunoEngineering Inc.
Filing Date: 2025-04-15
Form: 10-K
Item: Item 1A
Chunk 166
---
 experience, including over 20 years of public company experience and CFO experience in the field
of biotechnology and medical devices. Mr. Lytle currently serves as Chief Financial Officer of Actuate Therapeutics, Inc. since February
2024. Mr. Lytle previously served as Executive Vice President, Chief Financial Officer of Breathe Technologies, Inc. (“Breathe”),
a private venture-backed medical device company with an approved portable ventilator, from September 2018 to December 2019. Prior to Breathe,
Mr. Lytle served as Chief Financial Officer of Avid Bioservices, Inc. for 18 years, during which time the company advanced multiple products
in oncology and infectious diseases, while starting and expanding its biomanufacturing business to over $55 million in revenue. Prior
to joining Avid Bioservices, Mr. Lytle was employed by Deloitte.

The Board concluded that Mr. Lytle should serve as
a director because of his extensive experience with public companies in the biotechnology field along with his experience with product
development, corporate financing, mergers and acquisitions, and corporate governance.

 40 

Corporate
Governance

Meetings and Committees of the Board

We have three (3) standing committees of the Board,
consisting of the Audit Committee, the Compensation Committee, and the Corporate Governance and Nominating Committee. Our committees operate
under written charters adopted by the Board in November 2020, a copy of which is available on our website at www.mosaicie.com under the
Corporate Governance section of our Investors page or by written request to the Company at Mosaic ImmunoEngineering, Inc., 9114 Adams
Avenue, #202, Huntington Beach, California 92646, Attention: Corporate Secretary.

Due to the Company’s size, its limited operations,
and limited cash on hand during the year ended December 31, 2024, the Board of Directors were not actively engaged in all aspects each
committee charter.

Director Independence

Under Nasdaq Marketplace Rule 5605(a)(2), a director
will not be considered an “independent director” if, such director at any time during the past three years was an employee
of the Company, or if a director (or a director’s family member) accepted compensation from the Company (other than compensation
for board or board committee service) in excess of $120,000 during any twelve month period within the three years preceding the determination
of independence. In addition,